FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults

The U.S. Food and Drug Administration has granted approval for centanafadine, a new medication for the treatment of attention-deficit/hyperactivity disorder. Developed by Otsuka Pharmaceutical and marketed as Simtriyo, this drug is now available for both adults and children aged six years and older.

This approval marks a significant shift in clinical options as centanafadine stands as the first norepinephrine, dopamine, and serotonin reuptake inhibitor for ADHD. This mechanism provides a nonstimulant alternative for patients who require specific management of symptoms. The regulatory decision follows four phase 3 clinical trials that included participants from ages 4 to 55, demonstrating statistically significant symptom reduction compared to a placebo.

Clinical data indicates that the medication addresses core symptoms while showing positive effects on executive function. This includes improvements in areas such as time management, task initiation, and working memory. The reported safety profile for adults includes decreased appetite and headache, while younger populations may experience similar effects along with potential nausea or rash. Manufacturers noted that the drug exhibits a low potential for abuse or dependence.

Healthcare professionals view this as a necessary expansion of the available toolkit for a highly individualized condition. Because ADHD impacts people in different ways across school, work, and personal relationships, the introduction of a novel mechanism gives clinicians more control when traditional stimulant treatments do not produce the desired outcomes. The full study results from the extensive development program are expected to be shared at upcoming scientific meetings.